Gain Therapeutics (GANX) Assets Average (2021 - 2025)
Historic Assets Average for Gain Therapeutics (GANX) over the last 5 years, with Q3 2025 value amounting to $10.4 million.
- Gain Therapeutics' Assets Average fell 3800.8% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year decrease of 3800.8%. This contributed to the annual value of $15.4 million for FY2024, which is 2803.99% down from last year.
- Gain Therapeutics' Assets Average amounted to $10.4 million in Q3 2025, which was down 3800.8% from $10.7 million recorded in Q2 2025.
- In the past 5 years, Gain Therapeutics' Assets Average registered a high of $46.7 million during Q2 2021, and its lowest value of $10.4 million during Q3 2025.
- Moreover, its 5-year median value for Assets Average was $19.8 million (2023), whereas its average is $24.3 million.
- Per our database at Business Quant, Gain Therapeutics' Assets Average skyrocketed by 3285.29% in 2022 and then tumbled by 4626.26% in 2023.
- Quarter analysis of 5 years shows Gain Therapeutics' Assets Average stood at $40.8 million in 2021, then crashed by 35.71% to $26.2 million in 2022, then plummeted by 37.61% to $16.4 million in 2023, then fell by 19.01% to $13.2 million in 2024, then dropped by 21.46% to $10.4 million in 2025.
- Its Assets Average stands at $10.4 million for Q3 2025, versus $10.7 million for Q2 2025 and $11.9 million for Q1 2025.